GSK’s Zejula And Jemperli Boost Progression-Free Survival In Ovarian Cancer Trial

GSK plc has shared promising results from its phase III FIRST-ENGOT-OV44 trial, which investigated the combination of Zejula (niraparib) and Jemperli (dostarlimab) as a first-line treatment for advanced ovarian cancer. The study achieved its primary goal, showing that adding dostarlimab to the standard carboplatin-paclitaxel chemotherapy and niraparib maintenance, with or without bevacizumab, significantly improved progression-free survival (PFS). 

Hesham Abdullah, Senior Vice President and Global Head of Oncology, R&D, GSK, said in a statement, "As part of our focus in gynaecological cancers, we continue to evaluate the potential of this combination and look forward to sharing full results from the trial."

However, the secondary goal of extending overall survival didn’t reach statistical significance. Further analysis is underway, and GSK plans to present the findings to health authorities at an upcoming scientific conference. In terms of safety, the combination treatment was generally in line with the expected side effects of each individual drug.